



Marie Landry (Her) <marielandryceo@gmail.com>

Office of the Prime Minister / Cabinet du Premier ministre

Prime Minister | Premier Ministre <PM@pm.gc.ca>
To: Marie Landry <marielandryceo@gmail.com>
Cc: Jean-Yves Duclos <hcminister.ministresc@hc-sc.gc.ca>

Sat, Apr 1, 2023 at 12:31 PM

Dear Ms. Landry:

On behalf of Prime Minister Justin Trudeau, I would like to acknowledge receipt of your email.

Thank you for writing to the Prime Minister. You may be assured that your comments have been carefully reviewed.

In your correspondence, you raise an issue that falls within the portfolio of the Honourable Jean-Yves Duclos, Minister of Health, to whom I note you have also addressed your correspondence. While the Prime Minister appreciates the time you have taken to share your concerns, he will leave your comments to be considered by Minister Duclos.

Once again, thank you for taking the time to write.

J. Genge
Executive Correspondence Officer/Agente de correspondance
Executive Correspondence Services/
Services de la correspondance
de la haute direction

>>> From : Marie Landry marielandryceo@gmail.com Received : 30 Mar 2023 03:03:55 PM >>>

>>> Subject : THCP Regulations >>>>

Dear Prime Minister Justin Trudeau and Minister of Health Jean-Yves Duclos,

I am writing to you as a concerned citizen and a researcher in the field of hemp science, to bring to your attention a newly discovered compound in hemp plants, tetrahydrocannabiphorol (THCP).

THCP is a cannabinoid that has a much higher affinity for the CB1 receptor than THC, which means that it can produce more potent effects on the brain and body, even at lower doses. While THCP is not currently listed among the controlled cannabinoids under the Cannabis Act, I believe that it poses a potential risk for public health and safety and creates a legal loophole for producers and consumers of hemp-derived products.

Therefore, I urge you to consider adding THCP to the list of controlled cannabinoids under the Cannabis Act and establishing clear guidelines for testing and labeling of hemp products that may contain THCP. This will ensure that consumers are informed about the presence of this potent compound in the products they purchase and protected from any potential adverse effects.

I want to emphasize that this is not a call for the prohibition of THCP or any other cannabinoid that may be beneficial for cancer* patients or have other medical uses. Rather, it is a call for responsible regulation that allows access to these potentially helpful compounds while ensuring public safety.

Thank you for your attention to this matter. I hope that you will take swift action to regulate THCP and other THC analogs such as THC8 and THC10, and to establish a well-regulated market for all cannabis and hemp products.

Sincerely,

Marie Landry

*Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor - PubMed (nih.gov)<<https://pubmed.ncbi.nlm.nih.gov/15026328/>>

THCP.pdf, guzman_2006_anti_tumor.pdf